2022 Plenary Keynote Program

TUESDAY, 18 October

9:00 Welcome by Conference Organizer

09:15 Plenary Keynote Presentation - To Unlock the Power of AI, It’s Time To Stop Thinking Human
Richard LawRichard Law, PhD, Chief Business Officer, Exscientia
We’ve spent more than a decade hearing about the promise of AI for drug discovery and development. While that promise remains, it’s time to evolve our approach to unlock it. For all the buzz about AI, most companies are still using AI-assisted approaches, where humans focus on leveraging “good data” to fuel AI. Yet AI platforms, at heart, are data agnostic and make “decisions” far beyond human comprehension. No human can think in say, a 2,500 dimensional space. It’s too complicated, requires too much learning and too much data to be managed by humans. In short, humans are still calling the shots, using AI to problem-solve along the way. To unlock the power of AI for drug development and discovery, it is time to remain patient-centric, but stop thinking like humans and allow platforms to be designed to learn and become increasingly powerful and accurate with each incremental piece of data analyzed. In this talk, we’ll discuss the power of this approach and learn about industry players who are embracing this new “AI First” way of re-engineering drug discovery processes -- the leap to full, end-to-end integration of artificial intelligence – to maximize the potential of AI and machine learning to create better medicines faster and smarter.

10:15 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

16:45 Welcome by Conference Organizer

16:50 Plenary Keynote Introduction on "Data Chain of Custody" by Aneesh Karve, CTO of Quilt Data     

17:00 Plenary Keynote Presentation - Novartis Institute for Biomedical Research Data Strategy
Philippe MarcPhilippe Marc, PhD, Executive Director and Global Head, Integrated Data Sciences, Novartis Institutes for BioMedical Research
As part of the larger enterprise digital journey, and as part of the Novartis Research Master Plan, the Novartis Institute for Biomedical Research (NIBR) defined an updated data and data management strategy. This data strategy falls into a broader digital strategy which has many additional priority areas: Information technology, Artificial Intelligence, external science, decision support for drug discovery and early development to name a few. The NIBR data management strategy is based around four pillars:
1. Data Culture: Treat data as a corporate asset
2. Data Management: Structure and link data
3. Data Science: Develop products and insights based on data
4. Data Enterprise: Lead the enterprise on data

WEDNESDAY, 19 October

09:00 Welcome by Conference Organizer

09:05 Keynote Introduction

09:15 Plenary Keynote Panel Discussion - Digital Twins: The Virtual Future of Medicine
Peter CoveneyPeter Coveney, PhD, Professor of Physical Chemistry, Honorary Professor of Computer Science, and Director of the Centre for Computational Science, University College London
The purpose of building digital twins of ourselves is to create an organizational principle for modern predictive and personalized medicine. This talk will discuss the principles on which such digital twins may be constructed and used for clinical and healthcare purposes. The roles of multiscale modelling and simulation, artificial intelligence and uncertainty quantification will be described as essential elements in the drive to making actionable predictions from digital twin simulations.

Health and Safety